stockrow
Monday 9 November 2026
Export ACIU’s income statement to Excel — free account
AC Immune
ACIUAC Immune’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 86.1% from fiscal 2024.
- Revenue
- +152.3%
- EPS
- +36.0%
- Free cash flow
- +4.66%
Quarter to September 2026, against a year earlier
2.23
0.12
+5.69%
Follow ACIU
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (122.01%) | 0.00% | (113.59%) | (93.59%) |
+8 more TTM periods Free account |
|
| (33.75%) | 0.00% | (70.48%) | (37.92%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
414.09% | 0.00% | 639.62% | (1,753.26%) | |
Average Days of Receivables |
248.92 | 0.00 | 128.71 | 99.90 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | (0.84) | |
Free Cash Flow |
— | (83.67) | — | (84.67) | |
Capital Expenditures |
— | (1.21) | — | (1.07) | |
| Other line items | |||||
Cash ROIC |
0.00% | (59.83%) | 0.00% | (51.47%) | |
Accounts Receivable Turnover |
2.08 | 0.00 | 2.41 | 3.54 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
810.37% | — | 1,409.69% | 1,579.52% | |
Selling, General and Administrative Expense of Revenue |
275.49% | — | 426.99% | 450.44% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 123.03% | |
Interest Coverage |
(262.08) | — | (319.62) | (362.82) | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.98 | |
Depreciation/Fixed assets |
0.00 | 1.49 | 0.00 | 1.26 | |
Capex/Depreciation |
— | (0.33) | — | (0.35) | |
Revenue per Share |
0.10 | — | 0.05 | 0.04 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | (0.83) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.25 |
Columns are period end dates · fundamentals updated 6 Nov 2026